Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.


Results 1-4 of 4 (Search time: 0.001 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2010Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatmentKim, D.; Kim, D.; Kim, S.; Goh, H.; Pane, F.; Hughes, T.; Radich, J.; Lin, P.; Saglio, G.; Branford, S.; Martinelli, G.; Soverini, S.; Hochhaus, A.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2009Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNetBaccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R.; Goldman, J.; Hehlmann, R.
2012Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibWhite, D.; Radich, J.; Soverini, S.; Saunders, V.; Frede, A.; Dang, P.; Cilloni, D.; Lin, P.; Mongay, L.; Woodman, R.; Manley, P.; Slader, C.; Kim, D.; Pane, F.; Martinelli, G.; Saglio, G.; Hughes, T.